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ABSTRACT 
The introduction of oral fluid-based sampling is a relatively new concept in diagnostic 
medicine which has been rapidly adopted by the swine industry.  While the detection of 
porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A (IAV) in oral 
fluids has been well documented, research on the detection of most other pathogens requires 
additional research.   
 
Therefore, the objective of the study described in Chapter 3 was to describe PEDV detection 
patterns in growing pigs as shown by PEDV rRT-PCR testing of pen oral fluids.  While feces 
have traditionally been the dominant sample for PEDV detection, the research in Chapter 3 
describes oral fluids as a practical sample type for PEDV detection in growing pigs.  
Specifically, PEDV was detected in oral fluids until 69 days post exposure (DPE) which was 
longer than pen feces (55 DPE) and individual rectal swabs (41 DPE).  PEDV Cq values in 
oral fluids were comparable to PEDV Cq values in pen feces; however, PEDV Cq values in 
oral fluids and pen feces were significantly higher than individual rectal swabs.   
 
Chapter 3 described PEDV antibody kinetics, as shown by ELISA detection of IgA and IgG 
in individual pig serum and pen oral fluid samples and provided estimates of the cutoffs and 
performance of the PEDV "whole virus" IgA and IgG ELISAs.  PEDV antibody responses 
(IgG and IgA) were detected in both serum and oral fluid by 10 - 14 days post exposure.  The 
oral fluid PEDV IgA responses were particularly noteworthy with the maximum oral fluid 
IgA response reported at 97 DPE.   
 
The investigators evaluated anamnestic antibody responses of gilts previously exposed to 
PEDV through vaccination using serum, colostrum, and milk samples in Chapter 4.  Using 5 
different vaccination protocols (unvaccinated controls and one and/or 2 doses of either 
Vaccine A or Vaccine B), the investigators found that two doses of vaccine did not booster 
immune responses any more than one dose of vaccine did.  This was not unexpected since 
these gilts had been exposed to PEDV 8 months early.  Nevertheless, the results in Chapter 4 
demonstrate that vaccination can booster immune responses in previously exposed gilts.   
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CHAPTER 1.  THESIS ORGANIZATION 
This thesis is organized in five chapters. Chapter 1 contains a general introduction to the 
thesis organization.  Chapter 2 is a literature review titled “A review of the development and 
use of oral fluid diagnostics in swine medicine” which has been submitted to the Journal of 
Swine Health and Production for publication.  Chapter 3 is a scientific research paper titled 
“Porcine epidemic diarrhea virus (PEDV) detection and antibody response in commercial 
growing pigs” which was published in BMC Veterinary Research.  Chapter 4 is the final 
scientific research paper titled “Serum and mammary secretion antibody responses in PEDV-
immune gilts following PEDV vaccination”.  This chapter was published in the Journal of 
Swine Health and Production.  The final chapter contains general conclusions for the entire 
thesis. 
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CHAPTER 2.  A REVIEW OF THE DEVELOPMENT AND USE OF ORAL FLUID 
DIAGNOSTICS IN SWINE MEDICINE 
 
Jordan Bjustrom-Kraft1, Jane Christopher-Hennings2, Russ Daly2,  
Rodger Main1, Jerry Torrison3, Jeffrey Zimmerman1 
 
1Department of Veterinary Diagnostic and Production Animal Medicine,  
College of Veterinary Medicine, Iowa State University, Ames, Iowa  50011 
 
2Animal Disease Research & Diagnostic Laboratory, South Dakota State University, 
Brookings, South Dakota  57007 
 
3Minnesota Veterinary Diagnostic Laboratory, University of Minnesota, Saint Paul, 
Minnesota   55108 
 
Modified from a manuscript submitted to Journal of Swine Health and Production 
 
Summary 
Swine veterinarians in North America have been rapidly adopting the use of oral fluid-based 
testing methodologies for an ever-increasing number of systemic, respiratory, and enteric disease 
diagnostic applications in growing pigs and replacement breeding stock.  Since the first report of 
oral fluid testing in 2008, nucleic acid and/or antibody assays have been described in the 
peer-reviewed literature for many pathogens affecting swine.  Oral fluid-based diagnostics 
have a wide range of attributes that make its implementation desirable to swine producers 
and veterinarians including: caretaker- and pig-welfare friendly, cost-effective, efficacious, and 
broadly applicable across a number of pathogens and environments.  As evidence of the U.S. 
swine industry’s growing utility of oral fluids as a diagnostic tool, the cumulative number of 
swine oral fluid diagnostic tests conducted at three veterinary diagnostic laboratories in the upper 
Midwest (South Dakota State University, University of Minnesota, and Iowa State 
University) has increased from approximately 21,000 in 2010 to nearly 370,000 tests in 2016.  
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The objective of this review is to describe the developments in oral fluid diagnostics that 
have led to its widespread use and to highlight areas of concern as this technology is 
increasingly implemented by producers and veterinarians.   
 
Keywords:  Review, Swine, Oral Fluids, Diagnostics  
 
Introduction 
The first technical report on swine oral fluid diagnostics was presented at the 2005 
International PRRS Symposium where Simer et al.1 reported 20 of 24 pen-based oral fluid 
samples (~83%) and 17 of 24 serum samples (~71%) were porcine reproductive and 
respiratory syndrome virus (PRRSV) reverse transcription polymerase chain reaction (RT-
PCR) positive in finishing pigs.  The purpose of this review is to provide an update on the 
development and implementation of oral fluid diagnostics in swine medicine subsequent to 
this initial report.   
 
At the present time, detection of nucleic acid and/or antibodies in oral fluids has been 
documented for most of the major swine pathogens including: Actinobacillus 
pleuropneumoniae (APP),2,3 African swine fever virus (ASFV), 4,5 classical swine fever virus 
(CSFV)6, foot-and-mouth disease virus (FMDV),7,8 influenza A virus (IAV),9,10,11 Lawsonia 
intracellularis,12, Mycoplasma spp.,13,14,15 porcine circovirus type 2 (PCV2),16,17 porcine 
epidemic diarrhea virus (PEDV),18 porcine reproductive and respiratory syndrome virus 
(PRRSV),16,19,20,21,22 Senecavirus A,23 and others.  Field applications or research on the use of 
oral fluid diagnostics have been described in Australia,8 Belgium,24 Canada,25 England,26 
France,27 Germany,6 Italy,28 Japan,29 Malaysia,30 Poland,31 Spain,32 United Kingdom,33 the 
U.S.,16 Vietnam,34 and others.   
 
Oral fluid testing 
Many of the assays reported in the literature have only been described under research 
conditions, but it is reasonable to expect their future commercialized and/or adaption for 
routine use in diagnostic laboratories.  Even so, U.S. "swine-focused" diagnostic laboratories 
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began offering oral fluid-based testing to clientele in 2010.  The data provided in Tables 1-4 
and Figure 1 describe the number of oral fluid tests performed at Iowa State University 
(ISUVDL), University of Minnesota (UMNVDL), and South Dakota State University 
(SDSUVDL) over time.  The pathogens reviewed below are those for which testing is 
commonly performed and for which peer-reviewed literature is available.     
 
Most commonly applied oral fluid tests used in U.S. swine to date:  
PRRSV, IAV, and the porcine coronaviruses are the pathogens for which testing is most 
commonly performed and for which peer-reviewed literature is available. 
 
Porcine respiratory and reproductive syndrome virus (PRRSV)  
PRRSV was the first virus detected by RT-PCR in swine oral fluid samples.16  PRRSV oral 
fluid ELISAs for antibody detection have been routinely offered since 2010.  Of the 
~148,500 PRRSV tests performed in 2016, ~117,000 were for RNA detection (Tables 1 and 
2).   
 
 Nucleic acid detection          Prickett et al.16 first reported the detection of PRRSV in oral 
fluids collected in the field from 8-week-old pigs by quantitative RT-PCR (qRT-PCR).  Oral 
fluid PCR-positive results were coincident with RT-PCR-positive serum samples, i.e., 
showed 77% agreement.  Under experimental conditions, Prickett et al.19 reported that 
PRRSV RNA was detected in oral fluid samples from 3 to ~ 35 days post inoculation (DPI), 
with sporadic positives thereafter.  Similar results were obtained from individual boars 
inoculated with modified-live virus, type 1 PRRSV, or type 2 PRRSV.20  On DPI one, virus 
was detected in 10% of the boars sampled (7 of 69); by 3 DPI virus was detected in 100% of 
boars sampled (67/67).20  Cumulatively, the literature indicates that PRRSV RNA can be 
detected for at least 36 DPI in oral fluid samples.19,21,29,31,35,36,37,38,39,40  
 
Antibody detection          PRRSV IgG antibody is detected in oral fluids by ELISA between 7 
and 14 days after inoculation or vaccination.19,21,22,35,38,41  Kittawornrat et al.22, working with 
oral fluid samples from individually housed boars and a serum ELISA adapted to oral fluids 
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reported that IgM was detectable at 3 DPI, IgA at 7 DPI, and IgG at 8 DPI.22  Antibody 
responses in oral fluids mirrored the antibody ontogeny in serum.  Maternal PRRSV IgG is 
readily detected in pigs from PRRSV-positive sow herd and may be detected for up to 60 
days post-weaning.42  However, a PRRSV IgM-IgA (dual isotype) ELISA was shown to 
detect pig-specific IgM and IgA, even in the presence of maternal IgG.  PRRSV ELISA 
testing has been well documented in the literature and may provide a cost-effective approach 
to PRRS monitoring and surveillance.  
 
Influenza A virus (IAV)  
As shown in Tables 1 – 4, IAV oral fluid testing has been offered for routine testing since 
2010.  Of ~47,500 tests performed in 2016, ~42,300 were RT-PCRs (Table 1 and 2).   
 
Nucleic acid detection          Detmer, et al.43 first reported the detection of IAV in oral fluid 
samples from both experimentally and naturally infected pigs.  Under experimental 
conditions, IAV RNA was detected in oral fluids from 3 to 21 DPI; whereas, no IAV RT-
PCR-positive nasal swabs were detected past 7 DPI.35  Ramirez et al.39 reported highly 
variable detection patterns for IAV infection in 10 wean-to-finish barns.  Cumulatively, the 
literature indicates that IAV RNA can be detected from oral fluids, but widely variable 
detection patterns have been noted in the literature.26,31,35,44,45,46,47  
 
Virus isolation          Isolation of IAV from oral fluids in pigs is difficult, but reports of both 
success and failure may be found in the literature.  Detmer et al.43 and Allerson et al.44 were 
not able to isolate and sequence IAV from oral fluid samples.  However, Romagosa et al.47 
reported 51% (19/37) of RT-PCR positive oral fluid samples were also positive by virus 
isolation.  Similarly, Goodell et al.9 reported successful IAV virus isolation, but isolation was 
significantly less likely in oral fluids when compared to nasal swabs, particularly in 
vaccinated animals.  Additional research is needed to determine the best time to collect 
samples and the optimum laboratory protocol for successful IAV virus isolation.9,43 
 
Antibody detection          Panyasing et al.11 first reported detection of IAV-specific antibodies 
in oral fluid samples using a blocking ELISA based on the viral nucleoprotein (NP).  Using a 
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NP indirect ELISA, IAV antibody IgM responses peaked at 8 DPI and declined quickly 
thereafter while IgA and IgG were detected around 6 DPI and lasted through the conclusion 
of the study (42 DPI).10  In this same study, Panyasing et al.10 showed a rapid anamnestic 
oral fluid antibody response in vaccinated animals.  Cumulatively, the literature agrees that 
IAV antibodies can be detected in oral fluids as early as 6 DPI.10,34,45,48,49   
 
Porcine coronaviruses 
The majority of research on the porcine coronaviruses has focused on porcine epidemic 
diarrhea virus (PEDV).  This research strongly supports the use of oral fluids for PEDV 
detection, as discussed below.  Similar assumptions have been made for other porcine 
coronaviruses, i.e., TGEV and PDCoV, on the strength of this research.   
 
Porcine Epidemic Diarrhea Virus (PEDV)  
PEDV RT-PCR testing for oral fluids was implemented in 2013 and was used extensively 
thereafter, as reflected in the test numbers reported in Tables 1 - 4.  PEDV oral fluid antibody 
testing became available in 2016 (Table 3).  Of the ~74,500 PEDV tests conducted in 2016, 
~69,300 were for RT-PCR testing (Tables 1 and 2).   
 
Nucleic acid detection          Bjustrom-Kraft et al.18 authored the first peer-reviewed 
publication on the detection of PEDV in oral fluid samples by RT-PCR.  These authors found 
detectable levels of PEDV in rectal swabs, oral fluid, and pen fecal samples collected in the 
field following feedback exposure to PEDV.  Significant differences were detected between 
individual rectal swabs and pen-based oral fluid, i.e., oral fluids had lower Cq values 
indicating higher virus concentrations.  PEDV was detected in oral fluids for ~69 DPE.  
Under experimental conditions, Bower et al.50 reported detection of PEDV by RT-PCR in 
rectal swabs and oral fluids from 1 to 35 DPI in both sample types.   
 
Antibody detection          Bjustrom-Kraft et al.18 reported the detection of PEDV IgG and IgA 
in oral fluid samples collected 13 days after feedback exposure.  PEDV IgA S/P responses in 
oral fluid increased until 97 DPE whereas oral fluid IgG responses peaked at 13 DPE and 
declined thereafter.   
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Porcine deltacoronavirus (PDCoV) 
Under experimental conditions, Zhang et al.51 reported detection of PDCoV in oral fluids 
from 3-week-old pigs.  Individual rectal swabs, pen-based feces, and oral fluids were 
collected and PDCoV RNA was detected from 7 to 28 DPI, 7 to 14 DPI, and 7 to 35 DPI, 
respectively.  Homwong et al.52 evaluated PDCoV RT-PCR testing results from routine 
submissions (n = 602) to the University of Minnesota Veterinary Diagnostic Laboratory and 
found that oral fluid samples were more likely to test positive for PDCoV than feces.   
 
Less commonly used oral fluid tests in U.S. swine to date: 
Tests are available for several of pathogens for which little peer-reviewed literature is 
available.   
 
Porcine Circovirus type 2 (PCV2) 
As shown in Tables 1, 2, and 4, routine PCV2 oral fluid testing began in 2010.  Relatively 
few tests have been performed in recent years, reflecting the fact that vaccines are effective.53   
PCV2 was detected in oral fluids from each of the 3 sites with at least 1 to 2 positive samples 
in oral fluids by qPCR in 2008.16  Similar results were reported in PCV2-inoculated 11 week-
old-pigs where PCV2 was detected by PCR from 2 DPI until the conclusion of the study (~98 
DPI).17  Ramirez et al.39 reported 508 of 600 (85%) oral fluid samples were PCV2 positive 
by PCR in 10 wean-to-finish barns.  Van Cuong et al.34 reported a slightly lower PCV2 
detection rate (~61%) in 68 farms throughout Vietnam.  Under experimental conditions, 
PCV2 antibody (IgG, IgA, and IgM) was first reported in 2011.17  All PCV2-inoculated pigs 
seroconverted between 14 and 21 DPI, and antibody responses remained detectable through 
the conclusion of the study (~98 DPI).   
 
Senecavirus A (SVA) 
As shown in Tables 1 – 3, ~3,600 oral fluid-based tests have been conducted for SVA.  SVA 
detection in oral fluids has been documented under field conditions.23  While there were no 
clinical signs present, SVA was detected by RT-PCR in oral fluid samples at day zero in one 
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of the sites which corresponded with 9 of 10 positive serum samples at the same farm.  Little 
peer-reviewed research is available on SVA, but initial reports suggest oral fluids may be a 
useful and promising sample type for monitoring and surveillance of SVA.   
 
Bacterial pathogens 
Little peer-reviewed research is available on the detection of swine bacterial pathogens in 
oral fluids.  The bacterial pathogens that have been detected in oral fluids by PCR under 
experimental or field conditions and reported in the literature include: Actinobacillus 
pleuropneumoniae,2,54 Brachyspira spp.,55 Erysipelothrix rhusiopathiae,56 Haemophilus 
parasuis,54 Lawsonia intracellularis,12 Mycoplasma spp.,13,14,54 Pasteurella multocida,54 
Salmonella,12 and Streptococcus suis.54  
 
Bacterial pathogens for which antibodies are reportedly detected in oral fluids include:  
Actinobacillus pleuropneumoniae,2 Erysipelothrix rhusiopathiae,56 and Mycoplasma spp.15  
 
General Conclusions  
Pig production changed dramatically over the last several decades from small single-site 
farms to large multi-site production systems.57  These changes have allowed producers and 
veterinarians to achieve higher production efficiencies, but also coincided with the 
appearance of "production diseases", i.e., multifactorial diseases, and the appearance of new, 
high-impact pathogens, such as PRRSV and PEDV.58,59,60,61  
 
Diagnostic medicine needs to respond to new disease challenges with new methods capable 
of providing timely, accurate, informative results.  While individual pig samples, such as 
serum or swabs, have historically served this purpose, individual samples are not compatible 
with surveillance in contemporary swine production systems.  As an alternative to individual 
animal samples, Prickett et al.16 described the use of pen-based oral fluid samples (“rope 
testing”), for the detection of PRRSV and PCV2 in growing pigs.  Since this initial report, 
oral fluid-adapted nucleic acid and/or antibody tests have been reported for many of the 
major swine pathogens and oral fluid-based surveillance has been widely adopted by swine 
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producers and veterinarians.  This process will continue as more and better tests are adapted 
to the oral fluid matrix.  However, there are good reasons to exercise caution.  In particular, 
the peer-reviewed literature has shown that nucleic acid and antibody assays can be adapted 
to oral fluids, but the literature has also consistently shown that the procedures need to be 
carefully modified for optimum performance with the oral fluid matrix.62,63  Chittick et al.62 
and Gibert et al.32 working with PRRSV and Goodell et al.63 working with IAV found 
significant differences in test performance among RT-PCR protocols offered in veterinary 
diagnostic laboratories.  Once optimum protocols are identified, they should be broadly 
implemented to achieve reproducibility among diagnostic laboratories.  Overall, the 
development of oral fluid-based testing has changed the way we monitor disease in swine 
populations, but further careful work on the part of researchers and critical thinking on the 
part of producers and veterinarians will be needed to develop and use oral fluid diagnostics in 
the swine industry.   
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Tables  
Table 1.  Number of tests on oral fluid specimens by pathogen in 3 U.S. veterinary 
diagnostics laboratories* 
 
Pathogen 2010 2011 2012 2013 2014 2015 2016 
PRRSV 14,603 46,239 77,756 109,868 126,165 144,773 148,526 
IAV 4,785 16,495 34,297 46,940 48,688 48,895 47,454 
MHP 760 4,514 7,079 10,286 11,203 11,741 13,178 
PCV2 751 2,047 4,147 2,149 5,676 4,807 3,176 
APP - 37 4 93 14 287 3,306 
TGEV - 34 - 4,651 32,848 12,497 12,996 
PEDV - - - 14,361 75,965 76,063 73,494 
LI - - - 454 1,519 3,290 2,443 
PDCoV - - - - 21,393 46,366 58,513 
SVA - - - - - 1,597 3,598 
Other 64 1,630 1,919 1,804 2,010 2,595 2,755 
Total 20,963   70,996 125,202 190,606 325,481 352,911 369,439 
 
PRRSV: porcine reproductive and respiratory syndrome virus; IAV: influenza A virus; MHP:  
Mycoplasma hyopneumoniae; PCV2: porcine circovirus type 2; APP: Actinobacillus 
pleuropneumoniae; TGEV: transmissible gastroenteritis coronavirus; PEDV: porcine 
epidemic diarrhea virus; LI: Lawsonia intracellularis; PDCoV: porcine deltacoronavirus; 
SVA: Senecavirus A 
  
*Iowa State University, South Dakota State University, University of Minnesota   
18 
 
 
 
Table 2.  Number of nucleic acid (PCR) tests on oral fluid specimens in 3 U.S. veterinary 
diagnostics laboratories* 
 
Pathogen 2010 2011 2012 2013 2014 2015 2016 
PRRSV 14,251 43,464 64,984 84,835 96,715 110,650 116,671 
IAV 4,581 14,898 31,806 44,410 46,738 47,304 42,261 
PCV2 751 2,047 4,147 2,142 5,669 4,773 3,168 
MHP 750 4,514 7,056 10,271 11,201 11,708 13,169 
TGEV - 34 - 4,651 32,848 12,497 12,996 
PEDV - - - 14,361 75,931 76,048 69,324 
LI - - - 454 1,519 3,290 2,443 
PDCoV - - - - 21,393 46,365 58,513 
SVA - - - - - 1,597 3,533 
Other 64 1,584 1,923 1,881 2,024 2,863 2,886 
Total 20,397 66,541 109,916 163,005 294,038 317,095 324,964 
 
PRRSV: porcine reproductive and respiratory syndrome virus; IAV: influenza A virus; MHP:  
Mycoplasma hyopneumoniae; PCV2: porcine circovirus type 2; APP: Actinobacillus 
pleuropneumoniae; TGEV: transmissible gastroenteritis coronavirus; PEDV: porcine 
epidemic diarrhea virus; LI: Lawsonia intracellularis; PDCoV: porcine deltacoronavirus; 
SVA: Senecavirus A 
 
*Iowa State University, South Dakota State University, University of Minnesota   
19 
 
 
 
Table 3.  Number of antibody (ELISA) tests on oral fluid specimens in 3 U.S. veterinary 
diagnostics laboratories* 
 
Pathogen 2010 2011 2012 2013 2014 2015 2016 
PRRSV 43 1,575 11,224 23,785 28,107 32,564 30,051 
MHP 10 - - 4 1 33 8 
IAV - - 5 - - 2 3,960 
PEDV - - - - - 4 4,168 
APP - - - - - - 3,176 
SVA - - - - - - 60 
Total 53 1,575 11,229 23,789 28,108 32,603 41,423 
 
PRRSV: porcine reproductive and respiratory syndrome virus: MHP:  Mycoplasma 
hyopneumoniae: IAV: influenza A virus: PEDV: porcine epidemic diarrhea virus: APP: 
Actinobacillus pleuropneumoniae: SVA: Senecavirus A 
 
*Iowa State University, South Dakota State University, University of Minnesota   
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Table 4.  Number of oral fluid specimens submitted for nucleic acid sequencing in 3 U.S. 
veterinary diagnostics laboratories* 
 
Pathogen 2010 2011 2012 2013 2014 2015 2016 
PRRSV 300 919 1,444 1,223 893 1,524 1,718 
IAV 37 110 522 650 327 433 465 
PCV2 - - 6 7 7 34 8 
PEDV - - - - 34 3 2 
Other - - 23 27 1 4 10 
Total 337 1,029 1,995 1,907 1,262 1,998 2,203 
 
PRRSV: porcine reproductive and respiratory syndrome virus; IAV: influenza A virus; 
PCV2: porcine circovirus type 2; PEDV: porcine epidemic diarrhea virus 
 
*Iowa State University, South Dakota State University, University of Minnesota 
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Figures 
 
 
Figure 1.  Total number of oral fluid tests conducted at Iowa State University, South Dakota 
State University, and the University of Minnesota from 2010 to 2016 
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Abstract 
Longitudinal samples from two production sites were used to (1) describe the pattern of 
PEDV shedding (rRT-PCR) in individual rectal swabs, pen fecal samples, and pen oral fluids 
(OF); (2) describe the kinetics of PEDV antibody by ELISA (IgA, IgG) testing of pig serum 
and pen oral fluid samples; and (3) establish cutoffs and performance estimates for PEDV 
WV ELISAs (IgA, IgG).  Site One was PEDV positive; Site Two was PEDV negative.  On 
Site One, pen samples (feces and oral fluids) and pig samples (rectal swabs and serum) were 
collected both before and after the population was exposed to PEDV.  On Site Two, pen oral 
fluid samples and individual pig serum samples were negative for both PEDV antibody and 
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nucleic acid.  On Site One, PEDV was detected by rRT-PCR at 6 days post exposure (DPE) 
in all sample types.  The last rRT-PCR positives were detected in rectal swabs and oral fluids 
on 69 DPE.  IgG and IgA were detected in oral fluids and serum samples by 13 DPE.  
Analysis of the PEDV serum IgG WV ELISA data showed that a sample-to-positive (S/P) 
cutoff of ≥ 0.80 provided a diagnostic sensitivity of 0.87 (95% CI: 0.82, 0.91) and specificity 
of 0.99 (95% CI: 0.98, 1.00).  Serum IgG results declined slowly over the monitoring period, 
with 60% of serum samples positive (S/P ≥ 0.80) at the final sampling on 111 DPE.  Analysis 
of the PEDV oral fluid IgA WV ELISA found that a cutoff of S/P ≥ 0.80 provided a 
diagnostic sensitivity of 1.00 (95% CI: 0.92, 1.00) and a diagnostic specificity of 1.00 (95% 
CI: 0.99, 1.00).  The oral fluid IgA response increased through 97 DPE and began to decline 
at the last sampling on 111 DPE.  This study showed that oral fluid-based testing could 
provide an easy and “animal-friendly” approach to sample collection for nucleic acid and/or 
antibody-based surveillance of PEDV in swine populations. 
 
Keywords: PEDV, virus shedding, antibody kinetics, oral fluids, surveillance, IgG, IgA 
 
Introduction 
Porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense 
RNA virus in the family Coronaviridae.1  In susceptible herds, PEDV is characterized by the 
rapid onset of watery diarrhea and vomiting in pigs of all ages, with mortality approaching 
100% in suckling piglets.  First identified in 1978, PEDV was not considered a serious threat 
to swine health until devastating outbreaks of PEDV were reported in China in 2006 in 
association with previously unrecognized genetic variants.2  Thereafter, pathogenic strains 
producing clinical PED outbreaks were reported in Japan, Korea, Thailand, the Philippines, 
the Western hemisphere and subsequently Portugal and Germany.3,4,5  Thus, in a relatively 
short time, pathogenic PEDV has become pandemic.   
 
Since there is little possibility that PEDV will soon be eradicated, it is important to identify 
the means to prevent and/or control its effects:  PEDV management will necessitate 
monitoring PEDV in swine populations.  Therefore, the purpose of this study was to (1) 
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describe the patterns of PEDV shedding and detection in growing pigs as shown by PEDV 
real-time reverse transcription polymerase chain reaction (rRT-PCR) testing of individual pig 
rectal swabs, pen fecal samples, and pen oral fluids; (2) describe PEDV antibody kinetics as 
shown by enzyme-linked immunosorbent assay (ELISA) detection of IgA and IgG in 
individual pig serum and pen oral fluid samples; and (3) estimate the cutoffs and 
performance of the PEDV "whole virus" IgA and IgG ELISAs (WV IgA or IgG ELISA). 
 
Materials and Methods 
Experimental design 
Individual pig samples (rectal swabs and/or serum) and pen samples (fecal and/or oral fluid 
specimens) were collected longitudinally from one PEDV-positive commercial wean-to-
finish (WTF) barn in Missouri USA (Site One) and one PEDV-negative commercial WTF 
barn in Iowa USA (Site Two).  Fecal samples and oral fluids were tested by PEDV real-time 
reverse-transcriptase polymerase chain reaction (rRT-PCR).  Serum and oral fluid specimens 
were tested by two PEDV antibody WV ELISAs (IgA, IgG).  Testing results were used to 
describe PEDV shedding, establish the performance parameters of two PEDV WV ELISAs 
(IgA, IgG), and characterize antibody kinetics in a commercial pig production system.  This 
project was approved in writing both by an agent representing the livestock producer and the 
Iowa State University Office for Responsible Research.   
 
Site descriptions 
Site One was a 52-pen WTF barn stocked with ~800 pigs.  Pens were separated by metal 
gates, with 26 pens on each side of the walk way.  Pens were equipped with automatic 
feeders, bowl drinkers, and fully slatted floors.  The facility was designed with negative 
pressure tunnel ventilation and a deep pit (2.4 m) manure handling system.  Pigs were placed 
in the facility at the time of weaning (~3 weeks of age).  Pen samples (feces and oral fluids) 
and pig samples (rectal swabs and serum) were collected from the same 6 pens and a 
convenience sample of 5 pigs in each of the 6 pens at each sampling point.  Sampling began 
when the pigs were ~3 weeks of age and continued at ~2-week intervals for 27 weeks.  At 10 
weeks post-placement, i.e., when pigs were approximately 13 weeks of age, the producer 
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exposed the pigs (replacement gilts) to PEDV by mixing PEDV-positive fecal material with 
water and spraying feed and the pigs' oral-nasal area with the mixture using a hand-held 
sprayer.   
 
Site Two consisted of 3 identical 40-pen WTF barns, each stocked with ~900 pigs.  Pens 
were separated by solid walls, with 20 pens on each side of the walk way.  Pens were 
equipped with automatic feeders, bowl drinkers, and half-slatted floors.  The barns were 
constructed with natural ventilation and deep pit (2.4 m) manure handling systems.  Pigs 
were placed in the facility at the time of weaning (~3 weeks of age).  Pen oral fluid samples 
were collected from 36 pens (4 pens were not stocked) in each of the 3 barns and serum 
samples were collected from a convenience sample of 20 pigs in 2 pens (10 pigs per pen) in 
each barn.  Sampling began at 2 weeks post-placement (pigs were ~5 weeks of age) and 
continued weekly for a total of 9 samplings.  Individual pig rectal swabs and pen fecal 
specimens were not collected on Site Two. 
 
Sample collection 
Individual pigs were restrained and bled using 12.5 ml vacutainer tubes (Covidien, 
Minneapolis, MN USA) and 20 gauge x 3.81 cm (1 ½ in.) needles (Smiths Medical, Dublin, 
OH USA).  Blood samples were centrifuged at the laboratory, aliquoted, and stored at -20°C.   
 
Rectal swabs were collected from individual pigs using a commercial collection and transport 
system (StarswabII®, Starplex® Scientific Inc., Cleveland, TN USA) and stored at -20°C.  
Prior to testing, swabs were suspended in 1 ml of PBS (1X pH 7.4, Invitrogen Corporation, 
Carlsbad, CA USA), vortexed, and the liquid submitted for testing by PEDV rRT-PCR. 
      
Each pen-level fecal sample consisted of a convenience sample of 3-to-5 fresh semi-solid 
feces from throughout the pen.  Approximately equal portions of pen feces were placed in 
one 50 ml tube (Thermo Fisher Scientific, Waltham, MA USA) and stored at -20°C.  Prior to 
testing, samples were homogenized (stirred), ~1.0 g placed in 1 ml of PBS (1X pH 7.4 
Invitrogen Corporation) and submitted for PEDV rRT-PCR testing.   
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Pen-based oral fluids were collected as described elsewhere.6  In brief, 3-strand, 100% cotton 
rope was cut with the free end at shoulder height to the animals and suspended in the pen for 
20 to 30 min.  Pigs actively sought out and chewed the rope, leaving the strands moistened 
with oral fluids.  The rope was then removed from the pen and the wet portion placed in a 
single-use plastic bag.  Oral fluids were extracted by either manual or mechanical 
compression (wringer) of the wet rope, after which the fluid was decanted into 50 ml 
centrifuge tubes (Fisher Scientific) and stored at -20°C.   
 
For each site, all samples were completely randomized (random.org) within specimen type 
and submitted for testing at the end of the collection period. 
 
Diagnostic testing  
PEDV RNA extraction and real-time reverse transcriptase PCR (rRT-PCR)          In brief, 90 
µl of viral RNA was eluted from rectal swabs, fecal samples, and oral fluid specimens using 
the Ambion® MagMAXTM viral RNA isolation kit (Life Technologies, Carlsbad CA USA) 
and a KingFisher® 96 magnetic particle processor (Thermo-Fisher Scientific) following the 
procedures provided by the manufacturers.  Samples were tested for PEDV using a PEDV N 
gene-based rRT-PCR described in Madson et al.7 and performed routinely at the Iowa State 
University Veterinary Diagnostic Laboratory (ISU-VDL SOP 9.5263).  The forward primer 
sequence was 5’-CGCAAAGACTGAACCCACTAACCT-3’, the reverse primer sequence 
was 5’-TTGCCTCTGTTGTTACTTGGAGAT-3’, and probe sequence was 5’-FAM-
TGTTGCCAT/ZEN/TACCACGACTCCTGC-Iowa Black-3’.  The eluted RNA, primers, and 
probe were mixed with commercial reagents TaqMan® Fast Virus 1-Step Master Mix (Life 
Technologies) and the rRT-PCR reactions were conducted on an ABI 7500 Fast instrument 
(Life Technologies) in fast mode as follows: 1 cycle at 50°C for 5 min, 1 cycle at 95°C for 20 
s, 40 cycles at 95°C for 3 s, and 60°C for 30 s.  The results were analyzed using an automatic 
baseline setting with a threshold at 0.1.  Quantification cycle (Cq) values < 35 were 
considered positive for the corresponding coronavirus.  Data were reported as "adjusted 
Cqs": 
Adjusted Cq =  (35 – sample Cq) Equation 1 
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PEDV whole virus (WV) antibody ELISA          A U.S. prototype PEDV isolate, 
(USA/NC35140/2013) 8, was used in the PEDV WV antibody ELISA.  Each batch of 
approximately 1,000 ml of PEDV was propagated on Vero cells (ATCC CCL-81).  Briefly, 
one 75 cm2 flask (Thermo Fisher Scientific) of confluent Vero cells was inoculated with 3 ml 
of PEDV stock (1x105 TCID50 per ml) followed by the addition of 50 ml of cell culture 
medium composed of MEM 1X (Minimum Essential Medium, Life Technologies) 
supplemented with 0.3% tryptose phosphate broth, 0.02% yeast extract, 5 ug per ml Trypsin 
250 (Sigma-Aldrich, St.  Louis, MO USA), plus penicillin/streptomycin (10 U per ml), 
gentamicin (0.05 mg per ml) and amphotericin (0.25 μg per ml) as antibiotics.  After 3 to 4 
days at 37°C in a 5% CO2 incubator and when cytopathic effects were apparent, the contents 
of the flask (53 ml) were used to further expand the virus by inoculating each of 4 875 cm2 
flasks (BD Falcon, San Jose, CA) containing confluent Vero cell monolayers with 13 ml of 
the harvested PEDV plus 240 ml of culture medium.  After 3 to 4 days of incubation and 
when cytopathic effects were apparent, the fluid was frozen (-80°C), thawed, poured off, and 
then centrifuged at 4,000 x g for 15 min to remove cell debris.  The virus was pelleted by 
ultracentrifugation at 140,992 x g for 3 h, after which the pellet was washed twice with sterile 
PBS (1X pH 7.4) to remove culture medium components.  The purified virus was re-
suspended in 100ul PBS (1X pH 7.4) at a 1:100 dilution of the original supernatant volume 
and stored at -80°C.  Following titration and optimal dilution (PBS pH 7.4), polystyrene 96-
well microtitration plates (Nalge Nunc, Rochester, NY USA) were manually coated (100 μl 
per well) with the viral antigen solution and incubated at 4°C overnight.  After incubation, 
plates were washed 5 times, blocked with 300 μl per well of a solution containing 1% bovine 
serum albumin (Jackson ImmunoResearch Inc., West Grove, PA USA), and incubated at 
25°C for 2 h.  Plates were then dried at 37°C for 4 h and stored at 4°C in a sealed bag with 
desiccant packs.  The performance of each lot of plates was standardized using a panel of 
reference PEDV negatives and positives.  Plate lots with a coefficient of variation ≥10% 
were rejected. 
 
ELISA conditions for the detection of anti-PEDV IgA and IgG antibodies in serum and oral 
fluid specimens, including coating and blocking conditions, reagent concentrations, 
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incubation times, and buffers, were identical.  Serum samples were diluted 1:50 and oral 
fluid samples were diluted 1:2, after which plates were loaded with 100 μl of the diluted 
sample per well.  Plates were incubated at 25°C (serum) or 37°C (oral fluid) for 1 h and then 
washed 5 times with PBS (1X pH 7.4).  Positive and negative plate controls, i.e., antibody-
positive and -negative experimental serum samples, were run in duplicate on each ELISA 
plate.   
 
To perform the assay, 100 μl of peroxidase-conjugated goat anti-pig IgG (Fc) antibody 
(Bethyl Laboratories Inc., Montgomery, TX USA) diluted 1:20,000 for serum and 1:3,000 
for oral fluid samples or goat anti-pig IgA (Bethyl Laboratories Inc.) diluted 1:7,000 for 
serum and 1:3,000 for oral fluid samples was added to each well and the plates incubated at 
25°C (serum) or 37°C (oral fluid) for 1 h.  After a washing step, the reaction was visualized 
by adding 100 μl of tetramethylbenzidine-hydrogen peroxide (Dako North America, Inc., 
Carpinteria, CA USA) substrate solution to each well.  After 5 min incubation at room 
temperature, the reaction was stopped by the addition of 50 μl of stop solution (1 M sulfuric 
acid) to each well.  Reactions were measured as optical density (OD) at 450 nm using an 
ELISA plate reader (Biotek® Instruments Inc., Winooski, VT USA) operated with 
commercial software (GEN5TM, Biotek® Instruments Inc.).  The antibody response in serum 
and oral fluid samples was represented as sample-to-positive (S/P) ratios calculated as: 
 
S/P ratio =  
(sample OD – negative control mean OD) 
Equation 2 
(positive control mean OD – negative control mean OD) 
 
Data analysis 
Statistical analyses were performed using commercial statistical software (SAS® Version 
9.4, SAS® Institute, Inc., Cary, NC) using test results on serum (Site One, n = 330; Site Two, 
n = 540), oral fluid (Site One, n = 66; Site  2, n = 972), rectal swabs (Site One, n = 330), and 
pen feces (Site One, n = 66).  A mixed-effects repeated measures model (Proc GLIMMIX) 
was used to analyze the association between the detection of PEDV by rRT-PCR and the 
variables of interest, i.e., sample specimen (oral fluids, rectal swab, pen feces, serum) and 
day post exposure (DPE) using pen as a random effect.  Fixed effects were considered 
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significant at α = 0.05.  Differences in the proportion of PEDV rRT-PCR positive oral fluid, 
rectal swab, and pen feces was compared using the Fisher Exact Test.  Point and interval 
estimates of the sensitivity and specificity of the PEDV WV IgG and IgA ELISAs for serum 
and oral fluid samples were calculated using the exact Binomial formula and confidence 
intervals. 
 
Results 
PEDV rRT-PCR          On Site Two, all oral fluid samples (n = 972) collected during the 
monitoring period were PEDV rRT-PCR negative.   
 
On Site One, PEDV was detected in individual rectal swabs, pen fecal samples, and pen oral 
fluids by rRT-PCR collected for 10 weeks post exposure (Figure 1A), i.e., through 69 DPE 
(23 weeks of age).  An analysis of the adjusted rRT-PCR Cq values showed differences in 
the concentration of PEDV in the three sample types over time (p = 0.0005).  The 
concentration of PEDV was higher in pen fecal samples compared to rectal swabs (p = 
0.0001) and oral fluids (p = 0.0088) at 6 DPE.  Thereafter, no difference was detected in the 
concentration of virus in oral fluid and pen fecal samples through 69 DPE.  In contrast, the 
concentration of PEDV in rectal swab samples was significantly lower than in pen fecal 
samples and oral fluid samples at 13, 27, and 41 DPE (15, 17, 19 weeks of age) (p ≤ 0.002).   
 
An analysis of the proportion of rRT-PCR positive samples (Figure 1B) found differences 
among specimen types at 27, 41, and 55 DPE (17, 19, 21 weeks of age) (Fisher’s Exact Test, 
p < 0.03).  No differences were found between pen fecal samples and oral fluid samples over 
the monitoring period, except at 55 DPE when 6 of 6 oral fluid and 1 of 6 pen fecal samples 
were positive (p = 0.015).  However, the proportion of positive oral fluid specimens was 
significantly greater than rectal swabs at 27, 41, and 55 DPE (17, 19, 21 weeks of age) (p < 
0.02).  Likewise, the proportion of positive pen fecal samples at 41 DPE was significantly 
greater than rectal swabs (p = 0.0012). 
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PEDV whole virus (WV) antibody ELISA          On Site One, PEDV IgG and IgA were 
detected in all oral fluid and serum samples collected after 13 DPE (≥ 15 weeks of age).  As 
shown in Figures 2A and 3A, the oral fluid IgA S/P responses increased until 97 DPE (27 
weeks of age), whereas the serum IgA response peaked at 27 DPE (17 weeks of age).  
Figures 2B and 3B show the percent positive oral fluid samples and serum samples, 
respectively, for three S/P cutoffs.  Oral fluid (n = 972) and serum samples (n = 540) from 
Site Two were used as a source of PEDV negative samples for calculating cutoffs and 
performance estimates for the PEDV WV IgA and IgG ELISAs using the exact Binomial 
formula and confidence intervals (Table 1).   
 
Discussion 
The first objective of this study was to compare the detection of PEDV by rRT-PCR in rectal 
swabs, pen fecal samples, and oral fluid samples from pigs housed in commercial WTF 
facilities.  Specifically, comparisons were made among specimens in the duration of PEDV 
detection, proportion of positive samples, and concentration of virus in positive samples.    
 
PEDV was detected by rRT-PCR in rectal swabs, pen fecal samples, and oral fluid samples, 
with the last rRT-PCR positive rectal swabs collected at 69 DPE, pen fecal samples at 55 
DPE, and oral fluid samples at 69 DPE.  The fact that the cessation of PEDV detection 
coincided in fecal and oral fluid samples suggested that the environment did not serve as a 
reservoir for PEDV.  Previous publications provided data with which rectal swab data could 
be compared, but a comprehensive search of the literature did not find previous reports on the 
detection of PEDV in pen feces or pen-based oral fluid samples.  Madson et al.7 detected 
PEDV in rectal swabs through 24 days post inoculation (DPI) in 5 of 8 pigs inoculated at 3 
weeks of age with PEDV isolate US/Iowa/18984/2013.  Thomas et al.9 detected PEDV in 
rectal swabs for up to 21 DPI in 3-week-old pigs inoculated with PEDV isolate 
US/IN19338/2013.  Crawford et al.10 detected PEDV in rectal swabs for up to 42 DPI in 4-
week-old pigs infected by contact with a pig inoculated with PEDV isolate 
US/Colorado/2013.   
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The concentration of virus, as measured by rRT-PCR, differed among specimen types.  In 
particular, the concentration of PEDV nucleic acid in individual pig rectal swabs was 
significantly lower than oral fluid or pen-based fecal samples.  The concentration of virus in 
PEDV rRT-PCR positive oral fluid and pen-based fecal samples was not significantly 
different, except at 6 DPE.   
 
Differences were also detected among specimen types in the proportion of positive samples 
by time.  All oral fluid samples were rRT-PCR positive (6 of 6) through 55 DPE while the 
number PEDV rRT-PCR positive pen fecal samples and rectal swabs declined to ≤ 50 
percent at 27 DPE and later.  The lower concentration and lower rate of detection in rectal 
swabs could be attributed to the small volume of sample retained by the swab plus the effect 
of diluting each rectal swab in one ml of PBS prior to testing.  The lower rate of detection in 
pen floor fecal samples may reflect the non-uniform distribution of positive samples within a 
pen.  Previously, O’Connor et al.11 reported differences in Salmonella concentrations at 
various locations within a pen, i.e., the distribution of Salmonella within a pen was not 
uniform.   
 
Detection of PEDV by rRT-PCR using pen-based oral fluid samples has not previously been 
reported in the refereed literature.  Using the described procedures, one oral fluid sample 
from a pen provided detection equal to, or better than, rectal swab samples from 5 pigs in the 
pen.  Likewise, detection using oral fluid samples was equal to, or better than, detection 
using pen fecal samples.  Thus, the data indicated that oral fluids were an effective and 
sensitive specimen for herd-level rRT-PCR-based detection of PEDV in commercial growing 
pig environments. 
 
The second objective of the study was to describe PEDV serum and oral fluid IgA and IgG 
antibody kinetics and to estimate the performance of the PEDV "whole virus" IgA and IgG 
indirect ELISAs at different cutoffs.   
 
For serum IgG and IgA, respectively, a cutoff of S/P ≥ 0.80 provided diagnostic sensitivities 
of 0.87 (95% CI: 0.82, 0.91) and 0.58 (95% CI: 0.51, 0.65) and diagnostic specificities of 
32 
 
 
 
0.99 (95% CI: 0.98, 1.00) and 1.00 (95% CI: 0.99, 1.00).  Although both serum IgG and 
serum IgA were detected by 13 DPE, the serum IgG response provided better diagnostic 
performance than serum IgA (Table 1).  Serum IgG results declined slowly over the 
monitoring period, with 60% of serum samples positive (S/P ≥ 0.80) at the final sampling on 
111 DPE.  The utility of the PEDV WV serum IgA ELISA is a question for future research.  
In particular, research is needed to determine whether the detection of serum IgA, i.e., an 
antibody isotype necessarily produced by the piglet in response to infection, could be used to 
identify infection in the face of PEDV-specific colostral (IgG) antibody or whether serum 
IgA response be used in a confirmatory assay to clarify equivocal PEDV WV IgG ELISA 
results.   
 
For oral fluid IgG and IgA, respectively, a cutoff of S/P ≥ 0.80 provided diagnostic 
sensitivities of 0.69 (95% CI: 0.53, 0.82) and 1.00 (95% CI: 0.92, 1.00) and diagnostic 
specificities of 0.97% (95% CI: 0.96, 0.98) and 1.00 (95% CI: 0.99, 1.00).  Although oral 
fluid IgG and IgA were detected by 13 DPE, the oral fluid IgA response gave better 
diagnostic performance than IgG.  Notably, the oral fluid IgA response increased through 97 
DPE and only began to decline at the last sampling on 111 DPE.   
 
There are no prior reports against which to directly compare the PEDV oral fluid antibody 
kinetics observed in the current study, but DeBuysscher and Berman12 reported a large 
increase in IgA-secreting cells within the salivary glands of pigs following oral exposure to 
another coronavirus, transmissible gastroenteritis virus (TGEV).  On the other hand, 
Brandtzaeg13 noted that enteric stimulation does not necessarily produce a strong salivary 
IgA response in humans.  Because of similarities in experimental design, these data may also 
be compared to oral fluid IgG and IgA responses reported for porcine reproductive and 
respiratory syndrome virus (PRRSV) and influenza A virus (IAV)14,15.  Kittawornrat et al.14 
evaluated PRRSV oral fluid IgG and IgA responses using pen-based field samples and 
experimental oral fluid samples.  Using a commercial PRRS serum antibody ELISA adapted 
to oral fluids, IgG was readily detected and provided a diagnostic sensitivity of 0.95 (95% 
CI: 0.92, 0.97) and specificity of 1.00 (95% CI: 0.99, 1.00).  In contrast, the IgA response in 
oral fluid was detectable, but weak and transient.  Panyasing et al.15 evaluated influenza A 
33 
 
 
 
virus IgG and IgA responses in oral fluids.  Unlike the PRRSV response, both anti-IAV IgG 
and IgA were readily detected in oral fluids by ~7 DPI and throughout the study (DPI 42).  
These studies suggest that oral fluid IgG and IgA kinetics vary among pathogens.  Thus, it 
will be critical to evaluate antibody isotype kinetics during the process of adapting antibody 
assays to the swine oral fluid matrix.   
 
For disease surveillance in swine populations, diagnostic specificity is paramount because 
false positives quickly erode confidence in test results.  Therefore, the investigators 
recommend a conservative S/P cutoff for serum and oral fluid samples, e.g., ≥ 0.80 for 
routine use.  However, diagnostic sensitivity and specificity were presented for several 
PEDV WV ELISA S/P cutoffs (Table 1) to allow users to interpret results in the context of 
specific circumstances. 
 
Conclusion 
The purpose of surveillance is to provide timely information on pathogen exposure and 
immune responses in swine populations in order to optimize health and prevent disease.  
Well-validated, reproducible, high-throughput nucleic acid and antibody assays are necessary 
to achieve this purpose.  This study showed that oral fluid-based testing could provide an 
easy and “animal-friendly” approach to nucleic acid and/or antibody-based surveillance of 
PEDV in swine populations.  In particular, the exceptional strength and duration of the 
PEDV IgA antibody response in oral fluids raises the question as to its ability to serve as an 
indicator of protective immunity; this is a question for future research.  
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Tables 
Table 1.  Porcine epidemic diarrhea virus (PEDV) whole virus (WV) ELISA diagnostic 
sensitivity (Se) and specificity (Sp) by specimen type, antibody isotype, and 
sample-to-positive (S/P) ratioa 
 
Oral fluid - PEDV WV IgG ELISA Oral fluid - PEDV WV IgA ELISA 
S/P Se (95% CI) Sp (95% CI) S/P Se (95% CI) Sp (95% CI) 
0.30 1.00 (0.92, 1.00) 0.86 (0.84, 0.89) 0.30 1.00 (0.92, 1.00) 0.88 (0.86, 0.90) 
0.40 1.00 (0.92, 1.00) 0.90 (0.88, 0.92) 0.40 1.00 (0.92, 1.00) 0.96 (0.94, 0.97) 
0.50 0.98 (0.87, 1.00) 0.93 (0.91, 0.94) 0.50 1.00 (0.92, 1.00) 0.98 (0.97, 0.99) 
0.60 0.88 (0.74, 0.96) 0.95 (0.93, 0.96) 0.60 1.00 (0.92, 1.00) 0.99 (0.99, 1.00) 
0.70 0.71 (0.55, 0.84) 0.96 (0.95, 0.97) 0.70 1.00 (0.92, 1.00) 1.00 (0.99, 1.00) 
0.80 0.69 (0.53, 0.82) 0.97 (0.96, 0.98) 0.80 1.00 (0.92, 1.00) 1.00 (0.99, 1.00) 
  
Serum - PEDV WV IgG ELISA Serum - PEDV WV IgA ELISA 
S/P Se (95% CI) Sp (95% CI) S/P Se (95% CI) Sp (95% CI) 
0.30 1.00 (0.98, 1.00) 0.95 (0.93, 0.96) 0.30 0.93 (0.88, 0.96) 1.00 (0.99, 1.00)  
0.40 0.99 (0.96, 1.00) 0.98 (0.97, 0.99) 0.40 0.90 (0.86, 0.94) 1.00 (0.99, 1.00) 
0.50 0.97 (0.93, 0.99) 0.99 (0.98, 1.00) 0.50 0.82 (0.76, 0.87) 1.00 (0.99, 1.00) 
0.60 0.95 (0.91, 0.86) 0.99 (0.98, 1.00) 0.60 0.73 (0.67, 0.79) 1.00 (0.99, 1.00) 
0.70 0.91 (0.86, 0.94)  0.99 (0.98, 1.00) 0.70 0.66 (0.59, 0.72) 1.00 (0.99, 1.00) 
0.80 0.87 (0.82, 0.91) 0.99 (0.98, 1.00) 0.80 0.58 (0.51, 0.65) 1.00 (0.99, 1.00) 
 
aS/P =  
(sample OD – negative control mean OD) 
(positive control mean OD – negative control mean OD) 
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Figures
 
 
Figure 1.  Detection of porcine epidemic diarrhea virus (PEDV) in pig rectal swabs, pen-
based oral fluids, and pen-based fecal specimens from Site One by rRT-PCR.  At 13 weeks 
of age, the producer exposed the pigs to PEDV-positive fecal material mixed with water 
using a hand-held sprayer.  A (above): Mean adjusted quantification cycle (Cq) (35 – sample 
Cq) of positive samples.  B (below): Proportion of positive samples.   
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Figure 2.  PEDV Whole Virus ELISA IgG and IgA responses in oral fluid samples following  
exposure to PEDV at 13 weeks of age.  A (above): Oral fluid IgG and IgA responses over 
time.  B (below): Proportion of positive oral fluid IgA samples at three different S/P cutoffs.   
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Figure 3.  PEDV Whole Virus ELISA IgG and IgA response in serum samples following 
exposure to PEDV at 13 weeks of age.  A (above): Serum IgG and IgA responses over time.  
B (below): Proportion of positive serum IgG samples at three different S/P cutoffs. 
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Abstract 
Producers need to identify and refine methods to prevent and/or control the effects of PEDV.  
In the sow herd, maintaining levels of immunity sufficient to protect neonatal pigs is one 
important aspect in the control of PEDV.  The objective of this study was to compare 
anamnestic responses to two commercially available PEDV vaccines.   PEDV antibody-
positive gilts (n = 36) in a commercial production system were randomly assigned to one of 
five vaccination protocols: 1) no vaccine (controls); 2) PEDV vaccine A (2 weeks pre-
farrow); 3) PEDV vaccine A (5 and 2 weeks pre-farrow); 4) PEDV vaccine B (2 weeks pre-
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farrow); and 5) PEDV vaccine B (5 and 2 weeks pre-farrow).  Serum, colostrum, and milk 
samples collected over the course of the study were tested for PEDV IgG, IgA, and 
neutralizing antibody (NA).  Results were analyzed (SAS® Institute, Cary, NC) for the effect 
of vaccination on IgG, IgA, and NA responses by sample type (serum, colostrum, or milk) 
and the association between serum antibody responses and antibody responses in mammary 
secretions.  Analysis of the data from 32 animals completing the study found that vaccine 
induced an anamnestic response, i.e., vaccinates had higher antibody levels than controls for 
most tests and specimens, but no difference was detected between one vs two doses of 
vaccine and few differences in response were detected for vaccine A vs B.  A positive, but 
weak, correlation was detected between IgG in serum and IgA in colostrum (p = .012; r = 
.44). 
 
Keywords: PEDV, swine, vaccination, IgG, IgA 
 
Introduction 
Porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense 
RNA virus belonging to the family Coronaviridae.1  In susceptible herds, PEDV infections 
are most notably characterized by the rapid onset of severe watery diarrhea and vomiting in 
pigs of all ages, with morbidity and mortality approaching 100% in suckling piglets.1  
Outbreaks of diarrhea were first described in Europe in the early 1970's, with the virus finally 
identified in 1978.2  By the mid-1980's, outbreaks were rarely reported in Europe and were 
most often associated with weaned pigs.1  In Asia, PEDV was reported as the causative agent 
of an acute diarrheal disease outbreak in 1982.  Distinct from Europe, PEDV outbreaks have 
been more clinically severe and significantly affecting swine health in Asia.1  Although the 
western hemisphere was previously free of the infection, PEDV was detected in the U.S. 
(Ohio) in April 2013, with outbreaks subsequently reported throughout the U.S. 3  Since its 
initial introduction into the Americas, PEDV has been reported in Mexico, Canada, parts of 
the Caribbean, and Central and South America.4 
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PEDV replicates in the cytoplasm of villus epithelial cells throughout the small intestine 
causing degeneration of enterocytes and leading to villous atrophy and a reduction of the 
villus height:crypt depth ratio.  Clinically, this results in diarrhea, vomiting, and 
dehydration.1,5  In endemically-infected herds, management practices to protect neonatal 
piglets against PED commonly include (1) sanitation and disinfection to reduce the viral load 
in the environment and (2) efforts to stimulate lactogenic immunity through intentional 
exposure of sows and gilts to PEDV and/or vaccinating breeding stock prior to farrowing 
with commercially available (killed or non-replicating) PEDV vaccines.  Neonatal piglets are 
particularly susceptible to the effects of PEDV infection, but PEDV-immune sows are able to 
help protect their piglets by providing "lactogenic" immunity.  That is, piglets can be 
protected from the effects of PEDV infection by the consumption of anti-PEDV antibodies in 
colostrum and milk from sows previously infected with PEDV.  In particular, IgG in 
colostrum has been shown to improve the survivability of PEDV-infected piglets and 
secretory IgA (sIgA) protects against enteric disease.6,7 
 
A key concept is that the development of effective maternal immunity against PEDV and 
other coronaviruses requires “productive” enteric infection.  That is, enteric viral replication 
must be sufficient to stimulate the development of IgA plasmablasts that then traffic to the 
mammary glands where they produce sIgA for mammary secretions.6  Because current 
PEDV vaccines available in the U.S. are inactivated, they cannot stimulate protective levels 
of lactogenic immunity in PEDV-naïve animals.  Regardless, parenteral PEDV vaccines may 
serve a valuable role in maintaining herd immunity by safely stimulating an anamnestic 
response in previously-infected dams.  To address this question, replacement gilts (n = 36) 
infected with PEDV at 13 weeks of age were vaccinated at 5 and/or 2 weeks pre-farrowing 
with one of two commercial PEDV vaccines.  The response to each vaccine was evaluated by 
comparing antibody responses in serum and mammary secretions collected over time post-
vaccination.   
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Materials and methods 
Experimental design 
PEDV antibody-positive gilts (n = 36) in a commercial production system were randomly 
assigned to one of five vaccination protocols: 1) no vaccine (controls); 2) PEDV Vaccine A-
one dose (2 weeks pre-farrow); 3) PEDV Vaccine A-two doses (5 and 2 weeks pre-farrow); 
4) PEDV Vaccine B-one dose (2 weeks pre-farrow); and 5) PEDV Vaccine B-two doses (5 
and 2 weeks pre-farrow).  Serum, colostrum, and rectal swab samples were collected within 
12 hours post-farrowing.  Milk samples were collected at 3, 10, and 21 days post farrowing 
(DPF).  Rectal swabs were tested by real-time reverse transcriptase polymerase chain 
reaction (rRT-PCR) to confirm the absence of PEDV shedding.  Serum, colostrum, and milk 
samples were tested by PEDV whole virus (WV) IgG and IgA ELISAs and for neutralizing 
antibody (NA) by PEDV fluorescent focus neutralization assay (FFN).  Thirty-two gilts 
completed the study, i.e., farrowed viable litters and provided a full complement of samples 
(Table 1).  Data were analyzed using a mixed-effect model to compare antibody responses in 
serum, colostrum, and milk.  This project was approved by the Iowa State University Office 
for Responsible Research. 
 
Vaccines 
Vaccine A was a conditionally licensed (June 2014), commercially-manufactured 
(HarrisvaccinesTM, Inc., Ames, IA), PED vaccine based on replicon particle (RP) technology.  
RPs are RNA vectors that can express foreign antigens in vivo because they contain 
nonstructural genes, but cannot replicate in the animal because they lack structural genes.  
The PED vaccine used in this study was an alphavirus-derived replicon particle vaccine 
expressing the PEDV spike gene, hence the vaccine was designed to stimulate an immune 
response against the PEDV spike glycoprotein.  The vaccine was labeled for intramuscular 
(IM) use in healthy swine 3 weeks of age or older.  Two 1 ml doses were recommended, with 
the second dose given ~3 weeks after the first.   
 
Vaccine B was a conditionally licensed (September 2014), commercially-manufactured 
(Zoetis, Inc. Florham Park, NJ), inactivated, adjuvanted PED vaccine derived from a virus 
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strain isolated in the U.S. (USA/Colorado/2013).  Vaccine B was labeled for IM use in 
healthy, pregnant sows or gilts.  Two 2 ml doses given 3 weeks apart were recommended, 
with the second dose given 2 weeks pre-farrowing.  In previously vaccinated sows, one dose 
2 weeks before farrowing was recommended.  
 
Animals 
Farm management intentionally exposed study animals to PEDV at 13 weeks of age (~8 
months prior to vaccination) by mixing PEDV-positive fecal material with water and 
spraying the feed and the pigs' oral-nasal area using a hand-held sprayer, as described 
elsewhere.8  At ~35 weeks of age, farm management selected animals for entry into a 
commercial breeding farm (Missouri, USA).  Prior to entry, individual serum and rectal swab 
samples were collected and tested to verify that each animal was PEDV serum antibody 
positive, but not shedding PEDV.  Gilts were bred by artificial insemination beginning at ~40 
weeks of age and assigned to one of four breed groups by farm management based on their 
projected farrowing date.   
 
Vaccination protocols 
A randomized block design was used in the study, with each of the five vaccination protocols 
allocated to each breed group (block):  1) no vaccine (controls); 2) one dose of Vaccine A at 
2 weeks pre-farrow; 3) one dose of Vaccine A at 5 and a second dose at 2 weeks pre-farrow; 
4) one dose of Vaccine B at 2 weeks pre-farrow; and 5) one dose of Vaccine B at 5 and one 
dose at 2 weeks pre-farrow.  Gilts within breed groups were randomly assigned to a 
vaccination protocol using a random sequence generator (random.org).    
 
Sample collection and processing 
Blood and fecal swab samples were collected from gilts at 5 weeks pre-farrow and within 12 
hours post-farrow.  Blood samples were centrifuged at the laboratory, aliquoted, and stored at 
-20°C.  Rectal swab samples were collected using a commercial collection and transport 
system (StarswabII®, Starplex® Scientific Inc., Cleveland, TN USA) and stored at -20°C.  
Prior to testing, swabs were suspended in 1 mL of PBS (1X pH 7.4, Invitrogen Corporation, 
Carlsbad, CA USA), vortexed, and the liquid submitted for testing by PEDV rRT-PCR.   
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Mammary secretions were collected within 12 hours of farrowing and 3, 10, and 21 days 
post-farrow.  Prior to collection, 1 ml of oxytocin (Bimeda-MTC Animal Health Inc., 
Cambridge, Ontario, Canada) was injected in the perivulvar region to stimulate colostrum 
and milk letdown.  At the laboratory, samples were aliquoted and stored at -20○C.  Prior to 
antibody testing, mammary secretions (colostrum/milk) were processed by centrifugation at 
13,000 x g for 15 min at 4°C to remove fat and debris.  Thereafter, Rennet (Mucor miehei, 
Sigma R5876) was added (5 µl of stock solution per ml of mammary secretion) to coagulate 
the defatted samples.  After incubation at 37°C for 30 min, samples were centrifuged for 15 
min at 2000 x g and the supernatant collected for antibody testing.  
 
PEDV RNA extraction and real-time reverse transcriptase PCR (rRT-PCR)          In brief, 90 
µl of viral RNA was eluted from rectal swabs, fecal samples, or oral fluid specimens using 
the Ambion® MagMAXTM viral RNA isolation kit (Life Technologies, Carlsbad CA USA) 
and a KingFisher® 96 magnetic particle processor (Thermo-Fisher Scientific, Waltham, MA 
USA) following the procedures provided by the manufacturers.  Samples were tested for 
PEDV using a PEDV N gene-based rRT-PCR described in Madson et al.9 and performed 
routinely at the Iowa State University-Veterinary Diagnostic Laboratory (ISU-VDL SOP 
9.5263).  The forward primer sequence was 5’-CGCAAAGACTGAACCCACTAACCT-3’, 
the reverse primer sequence was 5’-TTGCCTCTGTTGTTACTTGGAGAT-3’, and the probe 
sequence was 5’-FAM-TGTTGCCAT/ZEN/TACCACGACTCCTGC-Iowa Black-3’.  The 
eluted RNA, primers, and probe were mixed with commercial reagents (TaqMan® Fast Virus 
1-Step Master Mix, Life Technologies) and the rRT-PCR reactions were conducted on an 
ABI 7500 Fast instrument (Life Technologies) in fast mode as follows: 1 cycle at 50°C for 5 
min, 1 cycle at 95°C for 20 s, 40 cycles at 95°C for 3 s, and 60°C for 30 s.  The results were 
analyzed using an automatic baseline setting with a threshold at 0.1.  Quantification cycle 
(Cq) values < 35 were considered positive for PEDV.  
 
PEDV whole virus (WV) antibody ELISA          The PEDV WV ELISA has been fully 
described.8  In brief, U.S. prototype PEDV isolate (USA/NC35140/2013)10 was propagated 
on Vero cells (ATCC CCL-81) at 37°C in a 5% CO2 incubator.  After 3 to 4 days of 
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incubation, flasks were subjected to one freeze-thaw cycle, the contents harvested, and cell 
debris removed by centrifugation at 4,000 x g for 15 min.  Thereafter, the virus was pelleted 
by ultracentrifugation at 140,992 x g for 3 h and processed to produce a purified viral antigen 
solution.  The purified virus was re-suspended in 100ul PBS (1X pH 7.4) at a 1:100 dilution 
of the original supernatant volume and stored at -80°C.  Polystyrene 96-well microtitration 
plates (Nalge Nunc, Rochester, NY USA) were then manually coated (100 μl per well) with 
the viral antigen solution, incubated at 4°C overnight, washed 5 times, and then blocked with 
300 μl per well of a solution containing 1% bovine serum albumin (Jackson 
ImmunoResearch Inc., West Grove, PA USA).  The performance of each lot of plates was 
standardized using a panel of PEDV serum antibody negatives and positives.  Plate lots with 
a coefficient of variation ≥ 10% were rejected.   
 
ELISA conditions for the detection of anti-PEDV IgA and IgG antibodies in serum and 
colostrum/milk (defatted) samples, including coating and blocking conditions, reagent 
concentrations, incubation times, and buffers, were identical with the exception that goat 
anti-pig IgG (Fc) (1:20,000 for serum and colostrum/milk) or IgA (1:3,000 dilution for serum 
and 1:50,000 dilution for colostrum/milk) HRP-conjugated secondary antibody was used for 
the antibody isotype-specific ELISAs.  Serum and colostrum/milk samples were diluted 1:50, 
after which plates were loaded with 100 μl of the diluted sample per well.  Plates were 
incubated at 25°C for 1 h and then washed 5 times with PBST (1X pH 7.4 + 0.1% Tween-
20).  Positive and negative plate controls, i.e., antibody-positive and -negative experimental 
serum samples, were run in duplicate on each ELISA plate.  Thereafter, 100 μl of peroxidase-
conjugated goat anti-pig IgG (Fc) antibody (Bethyl Laboratories Inc., Montgomery, TX 
USA) was added to each well and the plates incubated at 25°C for 1 h.  After a washing step, 
the reaction was visualized by adding 100 μl of tetramethylbenzidine-hydrogen peroxide 
(Dako North America, Inc., Carpinteria, CA USA) substrate solution to each well.  After a 5 
min incubation at room temperature, the reaction was stopped by the addition of 50 μl of stop 
solution (1 M sulfuric acid) to each well.  Reactions were measured as optical density (OD) 
at 450 nm using an ELISA plate reader (Biotek® Instruments Inc., Winooski, VT USA) 
operated with commercial software (GEN5TM, Biotek® Instruments Inc.).  The antibody 
response in serum and colostrum/milk samples was expressed as sample-to-positive (S/P) 
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ratios calculated as: 
S/P ratio =  
(sample OD – negative control mean OD) 
Equation 1 
(positive control mean OD – negative control mean OD) 
 
Fluorescent Focus Neutralization Assay (FFN)          The fluorescent focus neutralization 
assay (FFN) was performed at the South Dakota Animal Disease Research and Diagnostic 
Laboratory using a protocol described by Odka et al..11  In brief, test and control serum 
samples or rennet-treated milk and colostrum samples were heat inactivated at 56°C for 30 
min, then serially diluted in serum-free modified Eagles medium (MEM) containing 1.5 μg 
per ml TPCK-treated trypsin in 96-well plates to achieve a final volume of 100 μl per well.  
Next, 100 μl of PEDV stock diluted to a concentration of 100 to 200 fluorescent focus units 
(FFU) per 100 μl was added to each well and plates were incubated at 37°C for 1 h.  Plates 
containing confluent 3-day-old monolayers of Vero-76 cells (ATCC CRL-1587) were 
washed 3 times with serum-free MEM prior to transfer of the serum-virus mixtures to 
corresponding wells of these plates.  After 1 h incubation at 37°C, the serum-virus mixture 
was removed, monolayers washed once with serum-free MEM and 150 μl per well 
replacement media (MEM with 1.5 μg per ml TPCK-treated trypsin) was added to each well.  
Plates were incubated 24 h at 37°C, then monolayers fixed for 15 min with 80% acetone in 
water, dried, and stained with fluorescein conjugated PEDV anti-nucleocapsid (N) protein 
monoclonal antibody SD6-29.  Titers were reported as the reciprocal of the greatest sample 
dilution resulting in a 90% or greater reduction in FFU relative to virus control well.  A FFN 
titer <20 was considered negative. 
 
Data analysis 
Statistical analyses were performed using commercial statistical software (SAS® Version 
9.4, SAS® Institute, Inc., Cary, NC) using test results on serum (n = 64), colostrum (n = 32), 
and milk samples (n = 96).  A nonparametric one-way analysis of variance (ANOVA) was 
used to test for differences among vaccination protocols for IgG, IgA, and NA by sample 
type (serum, colostrum, or milk).  A general linear model (Proc GLIMMIX) was used to 
make pairwise comparisons in antibody responses between vaccination protocols by sample 
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type.  Correlation (Proc CORR) was used to test the association between antibody responses 
(IgG, IgA, and NA) in serum (collected at farrowing) and antibody responses in colostrum or 
milk (3 DPF).  Antibody responses in milk were evaluated by repeated measures analysis 
(Proc GLIMMIX) using a compound symmetry covariance structure.  ID, sample type, and 
treatment were used as categorical variables.  Milk was used as a time factor and the 
response was the test result (IgG, IgA, NA).  Treatments (Control, Vaccine A, Vaccine B) 
and sample type were explanatory variables. 
 
Results 
All rectal swab samples (n = 64) collected from gilts at 5 weeks pre-farrow and within 12 
hours post-farrow were PEDV rRT-PCR negative.  Statistical analysis of serum antibody 
responses (IgG, IgA, NA) at 5 weeks pre-farrow, i.e., prior to vaccination, found no 
difference in the antibody test results among the 5 vaccination protocols.  Within vaccine 
vaccination protocols (A, B), comparison of test responses by specimen and time of 
collection found no difference between one dose vs two doses.  Therefore, the data were 
collapsed and analyzed on the basis of 3 vaccination protocols:  unvaccinated control, 
Vaccine A, and Vaccine B.  Results and statistically significant differences among the three 
vaccination protocols are given in Table 2 by specimen (serum, colostrum, milk) and test 
(IgG, IgA, NA).   
 
Compared to unvaccinated controls, gilts administered Vaccine A showed higher IgG in 
serum at farrowing (p = .0009) and colostrum (p = .002); higher IgA in colostrum (p = .01) 
and milk collected at 3 DPF (p = .05); and higher NA in serum at farrowing (p = .02), 
colostrum (p = .0001), and milk samples collected at 3 and 21 DPF (p ≤ .05).   
 
Compared to unvaccinated controls, gilts administered Vaccine B showed higher IgG in 
serum at farrowing (p = .0001), colostrum (p = .0001), and milk collected at 3 and 21 DPF (p 
< .04); higher IgA in serum at farrowing (p = .002) and colostrum (p ≤ .02); and higher NA 
in colostrum (p < .0001).   
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A comparison of antibody responses among vaccinates showed that gilts receiving Vaccine B 
had higher IgG responses in serum collected at farrowing (p = .0001) and in colostrum (p = 
.01) compared to Vaccine A.  No other significant differences were detected between the two 
vaccine groups.   
 
In vaccinated animals (Vaccine A and Vaccine B), IgG, IgA, and NA in milk declined (p ≤ 
.01) between 3 and 10 DPF, but not from 10 to 21 DPF.  In unvaccinated controls, no 
significant decline was detected in IgG, IgA, or NA responses.  
 
Among all groups (n = 32 gilts) and regardless of treatment, a positive correlation was 
detected between IgG antibody responses in serum collected at farrowing and IgG in 
colostrum (p < .0001; r = .73); likewise, between IgG in serum collected at farrowing and 
IgG in milk collected at 3 DPF (p = .007; r = .47).  No correlation was detected between IgA 
or NA in serum collected at farrowing and colostrum nor between serum and milk collected 
at 3 DPF.  In contrast, a positive correlation was detected between IgG in serum and IgA in 
colostrum (p = .012; r = .44), but not between IgG in serum and IgA in milk collected at 3, 
10, and 21 DPF.   
 
Discussion 
Our expectations for PEDV lactogenic immunity are primarily modeled on transmissible 
gastroenteritis virus (TGEV) research.  In TGEV, it is known that an effective lactogenic 
response requires an episode of enteric viral replication sufficient to stimulate the 
development of TGEV-specific IgA plasmablasts.  These plasmablasts then migrate to the 
mammary glands where they reside and produce the TGEV-specific secretory IgA (sIgA) 
present in mammary secretions.6  Secretory IgA antibodies in milk neutralize TGEV in the 
intestinal lumen and protect suckling piglets from clinical disease.1,12  In the same fashion, it 
is assumed that PEDV-specific sIgA protects piglets by neutralizing virus in the gut and/or 
blocking viral attachment to enterocytes.  For PEDV, it has also been shown that systemic 
antibodies, such as those received by the piglet in colostrum, are also involved in protection.  
Specifically, Poonsuk et al.7 showed that neonatal piglets with passive circulating PEDV 
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antibody returned to normal body temperature faster and experienced less mortality after 
PEDV inoculation compared to controls, although circulating anti-PEDV antibody did not 
improve piglet growth rates or reduce PEDV fecal shedding.  Thus, PEDV lactogenic 
immunity includes PEDV-specific antibodies in both colostrum and milk.   
 
Since its appearance in North America in April 2013, control of PEDV on commercial swine 
farms has been based on biosecurity, monitoring, and disease prevention.  The prevention of 
clinical PEDV has been largely based on a combination of strict sanitation to reduce viral 
exposure to neonates and stimulation of lactogenic immunity through intentional exposure of 
sows to PEDV.6  Ideally, lactogenic immunity could be established in PEDV-naïve animals 
through the use of vaccination, rather than exposure to live PEDV.  However, it has been 
shown highly-attenuated, live-virus, oral TGEV vaccines replicate poorly in the gut and 
induce low milk sIgA antibody titers.1  Presumably, modified-live PEDV vaccines may likely 
face the same hurdle,6 and no licensed modified-live PEDV vaccines are currently available 
for use in the US.  Nevertheless, there is a clear need to optimize the level of PEDV 
immunity in sow herds with the tools at hand.  Therefore, the aim of this study was to 
characterize the anamnestic antibody response of pregnant gilts (n = 32) exposed to live 
PEDV ~8 months earlier to two commercially-available PEDV vaccines (non-replicating or 
killed) administered 5 and/or 2 weeks pre-farrow.  All antibody responses (IgG, IgA, NA) in 
serum, colostrum, and milk samples collected at farrowing and/or post-farrowing were 
numerically higher in vaccinated animals than in unvaccinated control animals.  Numerical 
differences in vaccinates vs controls were not necessarily significantly different, but this 
could be attributed to the relatively small numbers of animals in the study.  There are no 
refereed publications against which to compare these data, but the results suggest that one 
dose of either Vaccine A or Vaccine B administered 2 weeks prior to farrowing is sufficient 
to produce a meaningful increase in lactogenic immunity in previously exposed sows.  This 
was not unexpected because these gilts already had been infected and responded 
immunologically to PEDV.8 
 
For the management of breeding herd PEDV immunity and to guide decisions regarding the 
use of PEDV vaccines, it would be useful to be able to predict the expected level of PEDV 
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antibody in colostrum and milk in pregnant animals prior to farrowing.  Analysis of the data 
generated in this study found that serum IgG antibody responses were reasonably predictive 
of colostral (p < .0001; r = .73) and day 3 milk (p = .007; r = .47) IgG antibody responses.  
These results are compatible with the fact that ~100 percent of IgG in colostrum comes from 
serum, whereas only ~30 percent of IgG in milk is derived from serum.13,14,15,16  In contrast, 
no correlation was detected between serum IgA or NA responses and IgA or NA responses in 
mammary secretions.  This was not unexpected given that only ~40 percent of IgA in 
colostrum and ~10 percent of IgA in milk is derived from the sow's serum.13,14  As mentioned 
previously, it is assumed that PEDV-specific sIgA plays a primary role in neutralizing virus 
in the gut and/or blocking viral attachment to enterocytes.  While paired PEDV serologic 
antibody testing of dams prior to and following vaccination may be useful for documenting 
individual sow responses to the administration of a killed PEDV vaccine, direct measurement 
of PEDV IgA and/or PEDV NA in the colostrum and/or milk will provide practitioners a 
more clinically relevant assessment of PEDV lactogenic immunity.  In the current study, 
PEDV IgA was measured using the PEDV WV ELISA, and PEDV NA was measured by 
PEDV FFN. 
 
Conclusions 
In conclusion, the tools currently available to swine producers and veterinarians for initiating 
and modulating PEDV humoral immune responses are exposure to live virus and boostering 
through vaccination with commercially available (non-replicating or killed) products.  The 
findings of this study suggest vaccination of previously exposed gilts with the commercially 
available PEDV vaccines provides a measurable increase in the PEDV lactogenic immunity 
present in the dam’s colostrum and milk.  However, two key questions for "fine-tuning" the 
use of PEDV vaccines in sow herds remain unanswered:  1) What level of lactogenic 
antibody is needed to fully protect neonates against the clinical effects of PEDV?; and 2) 
How can we test to predict the level of lactogenic immunity that a sow will provide her 
piglets?  Additional research is needed to address these questions for fully effective PEDV 
control in commercial sow herds.   
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Tables 
Table 1.  Experimental design 
 
 
 
Trt* Vaccination protocol Animals Samples collected 
1 Unvaccinated (control) 4 gilts 1. Serum at 5 weeks pre-farrow 
2. Serum at farrowing  
3.  Colostrum ≤ 24 hr post 
farrowing.  
4.  Milk at 3, 10 and 21 days post 
farrowing 
2 1 ml IM - 2 weeks pre-farrow 6 gilts 
3 1 ml IM - 5 and 2 weeks pre-farrow 8 gilts 
4 2 ml IM - 2 weeks pre-farrow 7 gilts 
5 2 ml IM - 5 and 2 weeks pre-farrow 7 gilts 
*Treatment 2, 3 - Harrisvaccines™ PEDV Vaccine; 4, 5 - Zoetis PEDV Vaccine, Killed Virus 
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Table 2.  Serum and mammary secretion antibody responses* (least square means) in PEDV-immune gilts following PEDV 
vaccination† 
 
Specimen 
(time of collection) 
Test Control (95% CI) Vaccine A (95% CI) Vaccine B (95% CI) 
Serum 
(5 weeks pre-farrow) 
IgG  (S/P)  1.61 (0.49, 2.73)  1.68   (1.27, 2.08)  1.72   (1.29, 2.16) 
IgA (S/P)  1.08  (-0.37, 2.54)  1.61   (0.84, 2.39)  1.61   (0.99, 2.22) 
FFN (titer)  17  (6, 48)  57   (26, 121)  59   (28, 126) 
Serum 
(≤ 24 hr post farrow) 
IgG  (S/P)  1.01  (-0.07, 2.10)  2.03‡   (1.72, 2.33)  2.81‡§   (2.64, 2.99) 
IgA (S/P)  2.30  (-1.36, 5.95)  3.83   (3.09, 4.58)  4.27‡   (3.56, 4.97) 
FFN (titer)  135  (1, 12607)  950   (502, 1810)  610   (329, 1130) 
Colostrum 
(≤ 24 hr post farrow) 
IgG  (S/P)  1.31  (0.28, 2.34)  2.43‡   (2.03, 2.83)  2.98‡§   (2.76, 3.20) 
IgA (S/P)  0.63  (0.26, 1.00)  1.18‡   (0.97, 1.39)  1.32‡   (1.12, 1.53) 
FFN (titer)  160  (21, 1198)  3121‡   (1927, 5053)  2207‡   (1494, 3261) 
Milk 
(3 days post farrow) 
IgG  (S/P)  0.18  (-0.06, 0.42)  0.83   (0.46, 1.21)  0.98‡   (0.55, 1.40) 
IgA (S/P)  0.46  (0.07, 0.85)  0.87‡   (0.65, 1.09)  0.85   (0.62, 1.08) 
FFN (titer)  160  (65, 394)  1344‡   (601, 3023)  610   (260, 1430) 
Milk 
(10 days post farrow) 
IgG  (S/P)  0.08  (-0.06, 0.23)  0.21   (0.03, 0.39)  0.31   (0.17, 0.44) 
IgA (S/P)  0.52  (-0.04, 1.07)  0.71   (0.51, 0.91)  0.74   (0.50, 0.98) 
FFN (titer)  80  (3, 2051)  277   (141, 538)  226   (93, 549) 
Milk 
(21 days post farrow) 
IgG  (S/P)  0.03  (-0.02, 0.08)  0.15   (0.06, 0.23)  0.19‡   (0.11, 0.26) 
IgA (S/P)  0.46  (0.02, 0.90)  0.72   (0.49, 0.94)  0.72   (0.48, 0.97) 
FFN (titer)  57  (4, 782)  320‡   (128, 799)  196   (87, 437) 
 
* PEDV Whole Virus IgG ELISA; PEDV Whole Virus IgA ELISA; PEDV FFN;  
† Vaccine A - Harrisvaccines™ 1 and 2 doses; Vaccine B - Zoetis 1 and 2 doses.  Within vaccine treatment groups (A, B), comparison 
of test responses by specimen and time of collection found no difference in one dose vs two doses.  Therefore, the data were 
collapsed and analyzed as unvaccinated control (n = 4), Vaccine A (n = 14), and Vaccine B (n = 14). 
‡ Significantly different from unvaccinated control group (p ≤ 0.05).   
§ Significantly different from Vaccine A
5
5
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CHAPTER 5.  GENERAL CONCLUSIONS 
Porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense 
RNA virus in the family Coronaviridae.1  In susceptible herds, PEDV infection is 
characterized by the rapid onset of watery diarrhea and vomiting in pigs of all ages, with 
mortality approaching 100% in suckling piglets.  PEDV was not considered a serious threat 
to swine health until the emergence of virulent strains in China in 2006.2  In 2013, a 
genetically similar pathogenic strain of PEDV was found in the United States.3  Within a few 
months of its introduction into the U.S., it became clear that PEDV would not be easily 
eradicated, thus making it all the more important to identify the means to prevent and/or 
control its effects.  Specifically, the purpose of surveillance is to provide timely information 
on pathogen exposure and immune responses in swine populations in order to optimize swine 
health and prevent disease.  Well-validated, reproducible, high-throughput nucleic acid and 
antibody assays are necessary to achieve this purpose.  Chapter 3 results showed that oral 
fluid-based testing could be used to detect PEDV by rRT-PCR and/or ELISA.  In particular, 
the exceptional strength and duration of the PEDV IgA antibody response in oral fluids raises 
the question as to its ability to serve as an indicator of protective immunity which is a 
question for future research. 
 
Another important tool for means of prevention and control of PEDV is vaccination.  At the 
present time, only two PEDV vaccines (non-replicating or killed) are available in the U.S.  In 
addition to exposure to live virus, vaccination is a potential tool for boostering the humoral 
immune response of previously exposed animals.  In Chapter 4, the results showed no 
significant difference between the two vaccine products; thus, either vaccine would be 
effective for enhancing PEDV immunity.  Likewise, using one dose of either Vaccine A or 
Vaccine B was found to be sufficient for boostering the immune response in gilts previously 
exposed to PEDV.  While a modified live vaccine would be the ideal solution, thereby 
eliminating the need for feedback with live field virus, swine producers and veterinarians 
need to work with the vaccines currently available.  Therefore, the U.S. swine industry needs 
to ask two primary questions in terms of PEDV immunity and vaccination: 1) What level of 
lactogenic antibody is needed to fully protect neonates against the clinical effects of PEDV? 
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and 2) How can we test to predict the level of lactogenic immunity that a sow will provide 
her piglets?  Additional research is needed to address these questions for fully effective 
PEDV control in commercial sow herds.   
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